Table 1.
Baseline Characteristics of the Study Participants
| Variable | Early therapy n = 88 | Delayed therapy n = 62 | P value |
|---|---|---|---|
| Age, years | |||
| Mean ± SD |
34.86 ± 8.1 |
34.82 ± 7.6 |
0.97 |
| Gender, number (%): | |||
| Male |
74 (84.1%) |
52 (83.9%) |
|
| Female |
14 (15.9%) |
10 (16.1%) |
0.971 |
| BMI, kg/m2: | |||
| Mean ± SD |
17.9 ± 2.8 |
18.4 ± 2.1 |
|
| Hemoglobin, mg/dl | |||
| Mean ± SD |
10.6 ± 1.7 |
11.0 ± 1.9 |
|
| CD4 count, cells/mm3: | |||
| Median |
133 |
152 |
|
| (Range) |
(7 – 588) |
( 14 – 648 ) |
|
| log10viral load/ml: | |||
| Median |
5.36 |
5.30 |
|
| (Range) |
(2.42–5.88) |
(2.33–5.88) |
|
| Non TB OI’s : | |||
| number (%) |
12 (13.6%) |
10 (16.1%) |
0.671 |
| WHO Staging of HIV disease, number (%): | |||
| Stage 3 |
19(21.6%) |
15 (24.2%) |
0.70 |
| Stage 4 |
69 (78.4%) |
47 (75.8%) |
(overall) |
| Type of Tuberculosis, number (%): | |||
| PTB |
19 (21.6%) |
15 (24.2%) |
|
| PTB with Dissemination |
33 (37.5%) |
26 (41.9%) |
0.367 |
| EPTB |
18 (20.4%) |
15 (24.2%) |
(overall) |
| EPTB with Dissemination |
18 (20.4%) |
06 (09.7%) |
|
| DOTS Category of ATT, number (%): | |||
| Category I (2H3R3Z3E3 + 4H3R3) |
83 (94.3%) |
61 (98.4%) |
0.214 |
| Category II (2H3R3Z3E3S3 + 1H3R3Z3E3 + 5H3R3E3) | 05 (5.7%) | 01 (1.6%) | (overall) |
SD = Standard deviation; BMI = Body Mass Index; OI’s = Opportunistic Infections; WHO = World Health Organization; HIV = Human immunodeficiency virus; PTB = Pulmonary Tuberculosis; EPTB = Extra Pulmonary Tuberculosis; ATT = Antituberculosis treatment; H = Isoniazid (600 mg), R = Rifampicin (450 mg), Z = Pyrazinamide (1500 mg), E = Ethambutol (1200 mg), S = Streptomycin (750 mg).